Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer

References

• Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 1994;31:1–13.
   PubMed Web of Science ®Google Scholar
• Zhou BB, Sausville EA. Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res. 2003;5:413–421.
   PubMedGoogle Scholar
• Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3:421–429.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2014;134:1013–1023.
   PubMed Web of Science ®Google Scholar
• Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 1997;277:1497–1501.
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Chen H, Acharya MR, et al. Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clin Cancer Res. 2004;10:6840–6846.
   PubMed Web of Science ®Google Scholar
• Galaktionov K, Jessus C, Beach D. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 1995;9:1046–1058.
   PubMed Web of Science ®Google Scholar
• Goto H, Natsume T, Kanemaki MT, et al. Chk1-mediated Cdc25A degradation as a critical mechanism for normal cell cycle progression. J Cell Sci. 2019;132:pii: jcs223123.
   PubMed Web of Science ®Google Scholar
• Xia K, Lee RS, Narsimhan RP, et al. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol Cell Biol. 1999;19:4819–4824.
   PubMed Web of Science ®Google Scholar
• King C, Diaz HB, McNeely S, et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther. 2015;14:2004–2013.
   PubMed Web of Science ®Google Scholar
• Uto K, Inoue D, Shimuta K, et al. Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism. Embo J. 2004;23:3386–3396.
   PubMed Web of Science ®Google Scholar
• Ruegg UT, Burgess GM. Staurosporine, K0252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci. 1989;10:218–220.
   PubMed Web of Science ®Google Scholar
• Dent P, Jelinek T, Morrison DK, et al. Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases. Science. 1995;268:1902–1906.
   PubMed Web of Science ®Google Scholar
• Fu H, Xia K, Pallas DC, et al. Interaction of the protein kinase Raf-1 with 14-3-3 proteins. Science. 1994;266:126–129.
   PubMed Web of Science ®Google Scholar
• Conklin DS1, Galaktionov K, Beach D. 14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci U S A. 1995;92:7892–7896.
   PubMed Web of Science ®Google Scholar
• Dent P, Tang Y, Yacoub A, et al. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv. 2011;11:133–140.
   PubMedGoogle Scholar
• Milella M, Precupanu CM, Gregorj C, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005;11:2779–2795.
   PubMed Web of Science ®Google Scholar
• Fuse E, Kuwabara T, Sparreboom A, et al. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol. 2005;45:394–403.
   PubMed Web of Science ®Google Scholar
• Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61:5106–5115.
   PubMed Web of Science ®Google Scholar
• McKinstry R, Qiao L, Yacoub A, et al. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther. 2002;1:243–253.
   PubMed Web of Science ®Google Scholar
• Dai Y, Rahmani M, Pei XY, et al. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood. 2005;105:1706–1716.
   PubMed Web of Science ®Google Scholar
• Hawkins W, Mitchell C, McKinstry R, et al. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther. 2005;4:1275–1284.
   PubMed Web of Science ®Google Scholar
• Pei XY, Li W, Dai Y, et al. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells. Mol Pharmacol. 2006;70:1965–1973.
   PubMed Web of Science ®Google Scholar
• Hamed H, Hawkins W, Mitchell C, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther. 2008;7:616–629.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Youssefian LE, et al. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood. 2011;118:5189–5200.
   PubMed Web of Science ®Google Scholar
• Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther. 2007;6:789–801.
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Fisher PB, et al. MAPK pathways in radiation responses. Oncogene. 2003;22:5885–5896.
   PubMed Web of Science ®Google Scholar
• Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7:2955–2966.
   PubMed Web of Science ®Google Scholar
• Riesterer O, Matsumoto F, Wang L, et al. A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs. 2011;29:514–522.
   PubMed Web of Science ®Google Scholar
• Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther. 2008;7:2394–2404.
   PubMed Web of Science ®Google Scholar
• Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs. 2008;17:1331–1340.
   PubMed Web of Science ®Google Scholar
• Mani C, Jonnalagadda S, Lingareddy J, et al. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2019;21:104.
   PubMed Web of Science ®Google Scholar
• Mitchell C, Park M, Eulitt P, et al. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol. 2010;78:909–917.
   PubMed Web of Science ®Google Scholar
• Tang Y, Hamed HA, Poklepovic A, et al. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol. 2012;82:322–332.
   PubMed Web of Science ®Google Scholar
• Booth L, Cruickshanks N, Ridder T, et al. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther. 2013;14:458–465.
   PubMed Web of Science ®Google Scholar
• Klaeger S, Heinzlmeir S, Wilhelm M, et al. The target landscape of clinical kinase drugs. Science. 2017;358:pii: eaan4368.
   PubMed Web of Science ®Google Scholar
• Tse AN, Rendahl KG, Sheikh T, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res. 2007;13:591–602.
   PubMed Web of Science ®Google Scholar
• Daud AI, Ashworth MT, Strosberg J, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015;33:1060–1066.
   PubMed Web of Science ®Google Scholar
• Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res. 2012;18:6723–6731.
   PubMed Web of Science ®Google Scholar
• Italiano A, Infante JR, Shapiro GI, et al. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Ann Oncol. 2018;29:1304–1311.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts J, Poklepovic A, et al. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. Cancer Biol Ther. 2018;19:786–796.
   PubMed Web of Science ®Google Scholar